Galmed Pharmaceuticals (GLMD) Cash & Equivalents (2013 - 2026)

Galmed Pharmaceuticals' Cash & Equivalents history runs 14 years deep, the most recent figure standing at $4.1 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 13.91% year-over-year to $4.1 million; the TTM figure through Mar 2026 stood at $4.1 million (down 13.91% YoY), while the FY2025 annual figure was $4.0 million, up 602.82% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $4.1 million, up from $4.0 million in the prior quarter.
• The five-year high for Cash & Equivalents was $9.7 million in Q3 2024, with the low at $567000.0 in Q4 2024.
• The 5-year median for Cash & Equivalents is $3.0 million (2022), against an average of $3.6 million.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents plunged 80.18% in 2024, then surged 602.82% in 2025.
• Galmed Pharmaceuticals' Cash & Equivalents stood at $2.0 million in 2022, then jumped by 41.91% to $2.9 million in 2023, then slumped by 80.18% to $567000.0 in 2024, then soared by 602.82% to $4.0 million in 2025, then advanced by 3.11% to $4.1 million in 2026.
• Business Quant data shows GLMD's Cash & Equivalents at $4.1 million in Q1 2026, $4.0 million in Q4 2025, and $4.8 million in Q3 2025.